Loading viewer...
conference
Format: PDF conference
Phase IIb trial results presenting eftilagimod alpha (soluble LAG-3 fusion protein) combined with pembrolizumab versus pembrolizumab alone for first-line recurrent or metastatic head and neck squamous cell carcinoma. Study evaluated the efficacy of an MHC Class II agonist with anti-PD-1 immunotherapy in patients with CPS ≥1.
investor_presentation
63 Pages
Immutep AIPAC Phase IIb Eftilagimod Alpha Breast Cancer Biomarker Results
conferenceconference
1 Pages
conference
24 Pages
Illumina
Iridium Communications 2020 Deutsche Bank Telecom Conference
conferenceconference
20 Pages
Iridium Communications Inc.
AAM American Axle Manufacturing 2016 Barclays Automotive Conference
conferenceconference
26 Pages
American Axle Manufacturing Holdings
Stifel Financial 2016 Goldman Sachs Conference Presentation
conferenceconference
37 Pages
Stifel Financial Corp.